Cargando…
Cyclic peptide drugs approved in the last two decades (2001–2021)
In contrast to the major families of small molecules and antibodies, cyclic peptides, as a family of synthesizable macromolecules, have distinct biochemical and therapeutic properties for pharmaceutical applications. Cyclic peptide-based drugs have increasingly been developed in the past two decades...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
RSC
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729179/ https://www.ncbi.nlm.nih.gov/pubmed/35128405 http://dx.doi.org/10.1039/d1cb00154j |
_version_ | 1784626884123820032 |
---|---|
author | Zhang, Huiya Chen, Shiyu |
author_facet | Zhang, Huiya Chen, Shiyu |
author_sort | Zhang, Huiya |
collection | PubMed |
description | In contrast to the major families of small molecules and antibodies, cyclic peptides, as a family of synthesizable macromolecules, have distinct biochemical and therapeutic properties for pharmaceutical applications. Cyclic peptide-based drugs have increasingly been developed in the past two decades, confirming the common perception that cyclic peptides have high binding affinities and low metabolic toxicity as antibodies, good stability and ease of manufacture as small molecules. Natural peptides were the major source of cyclic peptide drugs in the last century, and cyclic peptides derived from novel screening and cyclization strategies are the new source. In this review, we will discuss and summarize 18 cyclic peptides approved for clinical use in the past two decades to provide a better understanding of cyclic peptide development and to inspire new perspectives. The purpose of the present review is to promote efforts to resolve the challenges in the development of cyclic peptide drugs that are more effective. |
format | Online Article Text |
id | pubmed-8729179 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | RSC |
record_format | MEDLINE/PubMed |
spelling | pubmed-87291792022-02-04 Cyclic peptide drugs approved in the last two decades (2001–2021) Zhang, Huiya Chen, Shiyu RSC Chem Biol Chemistry In contrast to the major families of small molecules and antibodies, cyclic peptides, as a family of synthesizable macromolecules, have distinct biochemical and therapeutic properties for pharmaceutical applications. Cyclic peptide-based drugs have increasingly been developed in the past two decades, confirming the common perception that cyclic peptides have high binding affinities and low metabolic toxicity as antibodies, good stability and ease of manufacture as small molecules. Natural peptides were the major source of cyclic peptide drugs in the last century, and cyclic peptides derived from novel screening and cyclization strategies are the new source. In this review, we will discuss and summarize 18 cyclic peptides approved for clinical use in the past two decades to provide a better understanding of cyclic peptide development and to inspire new perspectives. The purpose of the present review is to promote efforts to resolve the challenges in the development of cyclic peptide drugs that are more effective. RSC 2021-11-05 /pmc/articles/PMC8729179/ /pubmed/35128405 http://dx.doi.org/10.1039/d1cb00154j Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/ |
spellingShingle | Chemistry Zhang, Huiya Chen, Shiyu Cyclic peptide drugs approved in the last two decades (2001–2021) |
title | Cyclic peptide drugs approved in the last two decades (2001–2021) |
title_full | Cyclic peptide drugs approved in the last two decades (2001–2021) |
title_fullStr | Cyclic peptide drugs approved in the last two decades (2001–2021) |
title_full_unstemmed | Cyclic peptide drugs approved in the last two decades (2001–2021) |
title_short | Cyclic peptide drugs approved in the last two decades (2001–2021) |
title_sort | cyclic peptide drugs approved in the last two decades (2001–2021) |
topic | Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729179/ https://www.ncbi.nlm.nih.gov/pubmed/35128405 http://dx.doi.org/10.1039/d1cb00154j |
work_keys_str_mv | AT zhanghuiya cyclicpeptidedrugsapprovedinthelasttwodecades20012021 AT chenshiyu cyclicpeptidedrugsapprovedinthelasttwodecades20012021 |